Johnson & Johnson ($JNJ) and Pharmacyclics ($PCYC) nabbed the FDA's new breakthrough designation for their cancer drug ibrutinib, a promising late-stage therapy that will be put in the hands of regulators later this year. Report
| Presented by: Veeva Systems | December 10th, 2015
Join us for this webinar to learn how the Veeva TMF Maturity Model for Life Sciences can help you evaluate your TMF operating model and create a strategy that propels your organization along the TMF continuum. Register today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!